Cat. #154032
Human Imatinib Mesylate-Resistant Leukaemia Cell Line
Cat. #: 154032
Sub-type: Continuous
Unit size: 1x10^6 cells / vial
Availability: 10-12 weeks
Organism: Human
Disease: Cancer
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Steven Grant
Institute: Virginia Commonwealth University
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: Human Imatinib Mesylate-Resistant Leukaemia Cell Line
- Cancer type filter: Blood cancer
- Cancers detailed: Acute Lymphoblastic Leukemia (Ph+ ALL);Chronic Myelogenous Leukemia (CML)
- Research fields: Cancer
- Tool sub type: Continuous
- Parental cell: BV173
- Organism: Human
- Disease: Cancer
- Description: The human ALL cell line, named BV173, was altered to be imatinib resistant and contains the most frequently observed mutation (E255K) responsible for drug resistance in patients.
Handling
- Format: Frozen
- Unit size: 1x10^6 cells / vial
- Shipping conditions: Dry ice
References
- Cormack et al. 1992. J Mol Biol. 228(4):1078-90. PMID: 1474579.
- Structural requirements for the processing of Escherichia coli 5 S ribosomal RNA by RNase E in vitro.
